The Honest Answer Up Front

How fast do GLP-1s work? Faster than you expect on appetite. Slower than you expect on the scale. Most people feel hunger quiet down within 1 to 2 weeks of the first injection. Weight loss your doctor would call meaningful — 5% of body weight — usually arrives around months 2 to 4.

The famous numbers take far longer. Semaglutide’s landmark STEP 1 trial reported 14.9% average weight loss at 68 weeks. That is almost 16 months. Tirzepatide’s SURMOUNT-1 trial reached up to 20.9% — at 72 weeks. Not 12 weeks. Not one summer.

This guide maps the real timeline from published trial data, week by week. No compressed before-and-after ads. If you are still deciding between medications, our GLP-1 drug list breaks down every option — the shape of this curve applies to all of them.

How Fast Do GLP-1s Work? The Week-by-Week Table

Here is the whole journey in one table. The percentages are approximate averages read from the STEP 1 (semaglutide 2.4 mg) and SURMOUNT-1 (tirzepatide) trial curves. Your line will wobble around these — averages hide a lot of individual variation.

Timeframe What happens Approximate average loss
Weeks 1-2 Appetite quiets; starter dose builds tolerance 0-1%
Weeks 3-8 Dose climbs; food noise fades; side effects peak 1-4%
Weeks 9-16 Many people cross the 5% line 4-7%
Weeks 17-20 Full dose reached (semaglutide week 17; tirzepatide 15 mg takes 20+ weeks) 6-10%
Months 6-12 Longest steady stretch of the curve 10-15%
Weeks 60-72 Curve flattens; trial endpoints: 14.9% (STEP 1, 68 weeks) up to 20.9% (SURMOUNT-1, 72 weeks) 15-21%

One honesty note before the details. In STEP 1, 86.4% of semaglutide users lost at least 5% by week 68 — which means 13.6% did not, even after 16 months. These drugs are powerful. They are not universal.

Why the First Weeks Feel Slow on Purpose

The slow start is engineered, not accidental. The Wegovy label walks semaglutide up in five steps — 0.25, 0.5, 1, 1.7, then 2.4 mg — with four weeks at each stage, specifically to reduce stomach-related side effects. You spend the first 16 weeks below the dose the trials actually tested. Judging the drug in month one is like reviewing a movie from its opening logo. The fair checkpoint is months 3 to 4, when your dose finally matches the one behind the 14.9% headline.

Weeks 1 to 4: Appetite First, Scale Later

GLP-1 drugs copy a gut hormone. They slow stomach emptying and dial down appetite signals, per Cleveland Clinic — and that effect starts with the first dose. Many users report meals shrinking on their own within the first two weeks.

The scale is a different story. Semaglutide starts at 0.25 mg weekly, and the FDA’s Wegovy label treats that dose purely as an escalation step, not a treatment dose. Expect roughly 0 to 2% loss in month one. That is the plan working, not the plan failing.

This is also peak side-effect season. Nausea and stomach trouble cluster around dose starts and dose increases. Our Ozempic side effects guide covers what is normal, what passes, and what needs a call to your prescriber.

Months 2 to 3: The First Real Results

Somewhere between weeks 9 and 16, many people cross 5% total body weight loss. That threshold matters. NIDDK notes that losing 5-10% of starting weight is where measurable health benefits show up — blood sugar, blood pressure, cholesterol.

The trial curves back this window. STEP 1’s published semaglutide curve falls in a near-straight line through this stretch, with no magic jump — just steady weekly compounding while the dose keeps climbing toward full strength.

If nothing has moved by month 3 at a real dose, say so at your next check-in. Prescribers can adjust the dose, switch drugs, or investigate what else is going on. Waiting silently costs you months and money — at typical cash prices of $99 to $299 a month, per the July 2026 pricing pages we track, a stalled quarter is not cheap.

Months 4 to 6: Full Dose, Full Price

Semaglutide reaches its full 2.4 mg dose at week 17 on the standard label schedule. Tirzepatide’s top 15 mg dose takes at least 20 weeks of stepped increases. Only now is the medication doing everything the trials measured.

Your bill often peaks here too. Many telehealth sellers price by dose, and full-dose brand-name months run $199 to $449 on cash plans, per third-party pricing reports and the sellers’ own July 2026 pricing pages. Month five can cost triple month one. Our best semaglutide programs ranking flags which sellers hold one flat price at every dose and which escalate.

Budget for the timeline, not the intro offer. The trial results everyone quotes required 68 to 72 weeks of continuous medication — a first-month promo covers about 6% of that journey.

One Year In: The Plateau Is Part of the Plan

The curve does not drop forever. In STEP 1, average weight flattened near week 60 — about 14 months in — and the trial ended at week 68 with 14.9% average loss versus 2.4% for placebo. In SURMOUNT-1, the higher tirzepatide doses were still inching down at week 72, finishing at 19.5% to 20.9%, versus 3.1% for placebo.

A plateau is your body settling at a new set point. It is the expected shape of the data, not evidence the drug quit. The trap is quitting in response: NIDDK notes that weight commonly returns when medication stops.

So the plateau is really a budgeting question. At full-dose cash prices of $199 to $449 a month, a maintenance year runs roughly $2,400 to $5,400 before insurance or discounts. Know that number before week one, not week sixty.

How Fast Do GLP-1s Work Compared to the Ads?

Now run the marketing math. A social ad promises 20 pounds in a month. The best result in either landmark trial — 20.9% — took 72 weeks, inside a study where every participant also got a reduced-calorie diet and an exercise plan. Both STEP 1 and SURMOUNT-1 tested drug plus lifestyle change, never the drug alone.

Be most skeptical of compounded sales pages. Compounded semaglutide and tirzepatide are not FDA-approved — no compounded GLP-1 is — and the FDA has warned about dosing errors with unapproved GLP-1 products sold online. A faster-sounding timeline on a compounded seller’s page has zero published trials behind it.

The approved drugs earned their timelines the slow way. The FDA approved Wegovy in June 2021 and Zepbound in November 2023 on the strength of those 68- and 72-week studies. When a seller quotes you a shortcut, ask which trial it came from. There is a 100% chance the answer is none.

What Actually Changes Your Speed

A few levers genuinely move the timeline. The rest is noise.

  • Drug choice. Tirzepatide’s SURMOUNT-1 endpoint (up to 20.9%) beat semaglutide’s STEP 1 endpoint (14.9%) — different trials, so not a head-to-head, but the gap is why prescribers increasingly reach for tirzepatide first.
  • Dose. SURMOUNT-1 was dose-dependent: 15.0% at 5 mg, 19.5% at 10 mg, 20.9% at 15 mg over the same 72 weeks.
  • Staying on schedule. Missed refills and abandoned titration reset your progress. Cleveland Clinic lists stomach-related side effects as the top reason people struggle — managing them early keeps you on the curve.
  • The boring stuff. Diet and activity were built into both trials. Skipping them means chasing results the studies never measured.

What does not speed things up: booster supplements, unverified microdosing protocols, and any plan that skips titration steps to save money — that usually buys side effects and a quit, not speed.

Support quality is the quiet variable. Programs differ enormously on provider check-ins, dose-adjustment flexibility, and refill reliability — exactly the things that keep you on the 68-week curve — and that is what our best GLP-1 programs ranking scores, fine print and all.